TABLE 3

Comparison of peak expiratory flow (PEF) measured in the morning and evening after 14 days of treatment (pharmacodynamics analysis set)

PEF L·min−1
LS means (90% CI)LS means difference (90% CI)
Morning mean
 IND/GLY/MF a.m. versus placebo#489.6 (456.2–523.1) versus 417.5 (384.1–450.9)72.1 (61.3–82.9)
 IND/GLY/MF p.m. versus placebo#504.4 (471.0–537.9) versus 417.5 (384.1–450.9)86.9 (76.1–97.8)
 IND/GLY/MF a.m. versus IND/GLY/MF p.m.489.6 (456.2–523.1) versus 504.4 (471.0–537.9)–14.8 (–25.6––4.1)
Evening mean
 IND/GLY/MF a.m. versus placebo#522.0 (488.7–555.4) versus 449.0 (415.7–482.3)73.1 (61.9–84.2)
 IND/GLY/MF p.m. versus placebo#507.7 (474.3–541.0) versus 449.0 (415.7–482.3)58.7 (47.5–69.9)
 IND/GLY/MF a.m. versus IND/GLY/MF p.m.522.0 (488.7–555.4) versus 507.7 (474.3–541.0)14.4 (3.3–25.5)

n=35, unless otherwise stated. Morning PEF assessments were performed 24 h after the last morning dose and 12 h after the last evening dose. Analogously, the evening PEF assessments were performed 24 h after the last evening dose and 12 h after the last morning dose. LS: least squares; IND: indacaterol acetate; GLY: glycopyrronium bromide; MF: mometasone furoate. #: n=36.